Ranolazine, a novel agent for chronic stable angina

Area of Science:

• Cardiology
• Pharmacology
• Ischemic Heart Disease

Background:

• Chronic stable angina, a symptom of ischemic heart disease, affects millions annually due to an oxygen supply-demand mismatch.
• Existing therapies for chronic stable angina have limitations, necessitating novel treatment strategies.
• Ranolazine represents a new class of drug developed for chronic stable angina management.

Purpose of the Study:

• To provide an overview of chronic stable angina.
• To review current American College of Cardiology-American Heart Association (ACC-AHA) pharmacologic treatment guidelines.
• To explore the mechanism of action and clinical trial data for ranolazine.

Main Methods:

• Review of existing literature on chronic stable angina.
• Analysis of ACC-AHA treatment guidelines.
• Exploration of ranolazine's mechanism of action as a partial fatty acid oxidase inhibitor.
• Discussion of major phase III clinical trial results.

Main Results:

• Ranolazine works by enzymatic modulation, inhibiting partial fatty acid oxidase, rather than altering myocardial hemodynamics.
• Phase III clinical trials demonstrate ranolazine's efficacy in managing chronic stable angina.
• Ongoing trials aim to further define ranolazine's role in treatment algorithms.

Conclusions:

• Ranolazine is a novel therapeutic agent for chronic stable angina with a unique mechanism of action.
• Current evidence suggests ranolazine is most beneficial as adjunctive therapy to standard ACC-AHA treatment modalities.
• Further research is needed to fully elucidate the optimal role of ranolazine in managing chronic stable angina.